SCHEMBL30765723

SCHEMBL30765723

CCOC(=O)Cn1c(SC)ncc(NCc2ccc(OC)cc2OC)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
KDM4C Q9H3R0 1/20 0.46
ALDH1A1 P00352 3/20 0.42
TSHR P16473 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
TP53 P04637 1/20 0.42
GAA P10253 1/20 0.42
EGLN1 Q9GZT9 2/20 0.40
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
POLB P06746 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PDE9A O76083 1/20 0.39
LMNA P02545 2/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 3/20 0.38
CYP1A2 P05177 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765600 0.92 KDM4C (0.44) MAPTKDM4CALDH1A1TSHRNPSR1
SCHEMBL30765933 0.89 KDM4C (0.45) MAPTKDM4CALDH1A1TSHRNPSR1
SCHEMBL30765668 0.79 GAA (0.50) MAPTKDM4CALDH1A1TSHRNPSR1
SCHEMBL30765741 0.77 LMNA (0.41) MAPTALDH1A1POLBTDP1LMNA
SCHEMBL30765482 0.75 KDM4C (0.50) MAPTKDM4CALDH1A1TSHRNPSR1
SCHEMBL30765526 0.75 KDM4C (0.46) MAPTKDM4CALDH1A1TSHRNPSR1
SCHEMBL30765999 0.75 PDE4B (0.44) MAPTKDM4CALDH1A1TSHRNPSR1
SCHEMBL31558534 0.74 KDM4C (0.48) MAPTKDM4CALDH1A1TSHRNPSR1
SCHEMBL30766080 0.71 MEN1 (0.45) MAPTALDH1A1TSHRNPSR1TP53
SCHEMBL16993397 0.69 MAPT (0.65) MAPTKDM4CALDH1A1TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed